

If a conflict arises between a Clinical Payment and Coding Policy and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. "Plan documents" include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. Blue Cross and Blue Shield of Illinois may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSIL has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing Editor, American Medical Association, Current Procedural Terminology, CPT® Assistant, Healthcare Common Procedure Coding System, ICD-10 CM and PCS, National Drug Codes, Diagnosis Related Group guidelines, Centers for Medicare and Medicaid Services National Correct Coding Initiative Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Vitamin D Testing

Policy Number: CPCPLAB003

Version 1.0

Approval Date: September 5, 2025

Plan Effective Date: January 1, 2026

Description

The Plan has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

Reimbursement Information

1. For individuals with an underlying disease or condition which is specifically associated with vitamin D deficiency or decreased bone density (see **Note 1**) or for individuals suspected of hypervitaminosis of Vitamin D, 25-hydroxyvitamin D serum testing **may be reimbursable**.
2. As part of the total 25-hydroxyvitamin D analysis, testing for D2 and D3 fractions of 25-hydroxyvitamin D **may be reimbursable**.
3. For individuals who have documented vitamin D deficiency, repeat testing for serum 25-hydroxyvitamin D at least 12 weeks after the initiation of vitamin D supplementation **may be reimbursable** with the following restrictions:
 - a. Twice per year testing for monitoring of supplementation therapy until the therapeutic goal has been achieved.
 - b. Annual testing once the therapeutic range has been achieved.
4. For the evaluation or treatment of conditions that are associated with defects in vitamin D metabolism (see **Note 2**), 1,25-dihydroxyvitamin D serum testing **may be reimbursable**.
5. The following testing **is not reimbursable**:
 - a. Measurement of serum 1,25-dihydroxyvitamin D to screen for vitamin D deficiency.
 - b. Routine screening for vitamin D deficiency with serum testing in asymptomatic individuals and/or during general encounters

Note 1: Indications for serum measurement of 25-hydroxyvitamin D are as follows:

- A. Biliary cirrhosis and other specified disorders of the biliary tract
- B. Blind loop syndrome
- C. Celiac Disease
- D. Coronary artery disease in individuals where risk of disease progression is being considered against benefits of chronic vitamin D and calcium therapy
- E. Dermatomyositis
- F. Eating disorders
- G. Having undergone, or for those who have been scheduled for, bariatric procedures such as Roux-en-Y gastric bypass, sleeve gastrectomy, or biliopancreatic diversion with or without duodenal switch
- H. Hypercalcemia, hypocalcemia. or other disorders of calcium metabolism

- I. Hyperparathyroidism or hypoparathyroidism
- J. Individuals receiving hyperalimentation
- K. Intestinal malabsorption
- L. Inflammatory bowel disease (Crohn's disease and ulcerative colitis)
- M. Liver cirrhosis
- N. Long term use of anticonvulsants, glucocorticoids and other medications known to lower vitamin D levels
- O. Malnutrition
- P. Myalgia and other myositis not specified
- Q. Myopathy related to endocrine diseases
- R. Neoplastic hematologic disorders
- S. Osteogenesis imperfecta
- T. Osteomalacia
- U. Osteopetrosis
- V. Osteoporosis
- W. Pancreatic steatorrhea
- X. Primary or miliary tuberculosis
- Y. Psoriasis
- Z. Regional enteritis
- AA. Renal, ureteral, or urinary calculus
- BB. Rickets
- CC. Sarcoidosis
- DD. Stage III-V Chronic Kidney Disease and End Stage Renal Disease
- EE. Systemic lupus erythematosus

Note 2: Indications for serum testing of 1,25-dihydroxyvitamin D are as follows:

- A. Disorders of calcium metabolism
- B. Familial hypophosphatemia
- C. Fanconi syndrome
- D. Hyperparathyroidism or hypoparathyroidism
- E. Individuals receiving hyperalimentation
- F. Neonatal hypocalcemia
- G. Osteogenesis imperfecta
- H. Osteomalacia
- I. Osteopetrosis
- J. Primary or miliary tuberculosis
- K. Renal, ureteral, or urinary calculus
- L. Rickets
- M. Sarcoidosis
- N. Stage III-V Chronic Kidney Disease and End Stage Renal Disease

Procedure Codes

The following is not an all-encompassing code list. The inclusion of a code does not guarantee it is a covered service or eligible for reimbursement.

Codes
82306, 82652, 0038U

References

1. AAP. (2022). *Section on Endocrinology: Five Things Physicians and Patients Should Question*.
<https://downloads.aap.org/AAP/PDF/Choosing%20Wisely/CWEndocrinology.pdf>
2. ACOG. (2011). ACOG Committee Opinion No. 495: Vitamin D: Screening and supplementation during pregnancy. *Obstet Gynecol*, 118(1), 197-198.
<https://doi.org/10.1097/AOG.0b013e318227f06b>
3. Annema, W., Nowak, A., von Eckardstein, A., & Saleh, L. (2018). Evaluation of the new restandardized Abbott Architect 25-OH Vitamin D assay in vitamin D-insufficient and vitamin D-supplemented individuals. *J Clin Lab Anal*, 32(4), e22328. <https://doi.org/10.1002/jcla.22328>
4. Aspray, T. J., Bowring, C., Fraser, W., Gittoes, N., Javaid, M. K., Macdonald, H., Patel, S., Selby, P., Tanna, N., & Francis, R. M. (2014). National Osteoporosis Society vitamin D guideline summary. *Age Ageing*, 43(5), 592-595.
<https://doi.org/10.1093/ageing/afu093>
5. Avenell, A., Bolland, M. J., & Grey, A. (2018). 25-Hydroxyvitamin D - Should labs be measuring it? *Ann Clin Biochem*, 4563218796858.
<https://doi.org/10.1177/0004563218796858>
6. Awumey, E. M., Mitra, D. A., Hollis, B. W., Kumar, R., & Bell, N. H. (1998). Vitamin D metabolism is altered in Asian Indians in the southern United States: a clinical research center study. *J Clin Endocrinol Metab*, 83(1), 169-173.
<https://doi.org/10.1210/jcem.83.1.4514>
7. Bolland, M. J., Grey, A., & Avenell, A. (2018). Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. *Lancet Diabetes Endocrinol*. [https://doi.org/10.1016/s2213-8587\(18\)30265-1](https://doi.org/10.1016/s2213-8587(18)30265-1)
8. Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., Pessah-Pollack, R., McClung, M., Wimalawansa, S. J., & Watts, N. B. (2020). AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. *Endocr Pract*, 26(Suppl 1), 1-46. <https://doi.org/10.4158/gl-2020-0524suppl>
9. CDC. (2017). VDSCP: Vitamin D Standardization-Certification Program. VDSCP: Vitamin D Standardization-Certification Program

10. CDC. (2019). CDC Vitamin D Standardization-Certification Program. https://www.cdc.gov/labstandards/pdf/hs/CDC_Certified_Vitamin_D_Procedures-508.pdf
11. CDC. (2024). *Facts: Falls Are Serious and Costly*. https://www.cdc.gov/falls/data-research/facts-stats/?CDC_AAref_Val=https://www.cdc.gov/falls/facts.html
12. Chapuy, M. C., Pamphile, R., Paris, E., Kempf, C., Schlichting, M., Arnaud, S., Garnero, P., & Meunier, P. J. (2002). Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalys II study. *Osteoporos Int*, 13(3), 257-264. <https://doi.org/10.1007/s001980200023>
13. Crowe, F. L., Thayakaran, R., Gittoes, N., Hewison, M., Thomas, G. N., Scragg, R., & Nirantharakumar, K. (2019). Non-linear associations of 25-hydroxyvitamin D concentrations with risk of cardiovascular disease and all-cause mortality: Results from The Health Improvement Network (THIN) database. *J Steroid Biochem Mol Biol*, 195, 105480. <https://doi.org/10.1016/j.jsbmb.2019.105480>
14. Dawson-Hughes, B. (2023, May 16). *Causes of vitamin D deficiency and resistance*. Wolters Kluwer. <https://www.uptodate.com/contents/causes-of-vitamin-d-deficiency-and-resistance>
15. Dawson-Hughes, B. (2024, July 29, 2024). *Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment*. UptoDate. <https://www.uptodate.com/contents/vitamin-d-deficiency-in-adults-definition-clinical-manifestations-and-treatment>
16. Dawson-Hughes, B., Harris, S. S., Krall, E. A., & Dallal, G. E. (1997). Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *N Engl J Med*, 337(10), 670-676. <https://doi.org/10.1056/nejm199709043371003>
17. Dedeoglu, M., Garip, Y., & Bodur, H. (2014). Osteomalacia in Crohn's disease. *Arch Osteoporos*, 9, 177. <https://doi.org/10.1007/s11657-014-0177-0>
18. Demay, M. B., Pittas, A. G., Bikle, D. D., Diab, D. L., Kiely, M. E., Lazaretti-Castro, M., Lips, P., Mitchell, D. M., Murad, M. H., Powers, S., Rao, S. D., Scragg, R., Tayek, J. A., Valent, A. M., Walsh, J. M. E., & McCartney, C. R. (2024). Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*, 109(8), 1907-1947. <https://doi.org/10.1210/clinem/dgae290>
19. Ebell, M. H. (2019). Vitamin D Is Not Effective as Primary Prevention of Cardiovascular Disease or Cancer. *Am Fam Physician*, 100(6), 374.
20. El Amrousy, D., El Ashry, H., Hodeib, H., & Hassan, S. (2021). Vitamin D in Children With Inflammatory Bowel Disease: A Randomized Controlled Clinical Trial. *J Clin Gastroenterol*, 55(9), 815-820. <https://doi.org/10.1097/MCG.0000000000001443>
21. Fletcher, J., Cooper, S. C., Ghosh, S., & Hewison, M. (2019). The Role of Vitamin D in Inflammatory Bowel Disease: Mechanism to Management. *Nutrients*, 11(5). <https://doi.org/10.3390/nu11051019>
22. Glendenning, P., & Inderjeeth, C. A. (2012). Vitamin D: methods of 25 hydroxyvitamin D analysis, targeting at risk populations and selecting thresholds of treatment. *Clin Biochem*, 45(12), 901-906. <https://doi.org/10.1016/j.clinbiochem.2012.04.002>

23. Golden, N. H., & Abrams, S. A. (2014). Optimizing bone health in children and adolescents. *Pediatrics*, 134(4), e1229-1243. <https://doi.org/10.1542/peds.2014-2173>
24. Goulart, R. A., & Barbalho, S. M. (2022). Can vitamin D induce remission in patients with inflammatory bowel disease? *Ann Gastroenterol*, 35(2), 140-149. <https://doi.org/10.20524/aog.2022.0692>
25. Granado-Lorencio, F., Blanco-Navarro, I., & Perez-Sacristan, B. (2016). Criteria of adequacy for vitamin D testing and prevalence of deficiency in clinical practice. *Clin Chem Lab Med*, 54(5), 791-798. <https://doi.org/10.1515/cclm-2015-0781>
26. Hao, L., Carson, J. L., Schluskel, Y., Noveck, H., & Shapses, S. A. (2020). Vitamin D deficiency is associated with reduced mobility after hip fracture surgery: a prospective study. *The American Journal of Clinical Nutrition*, 112(3), 613-618. <https://doi.org/10.1093/ajcn/nqaa029>
27. Holick, M. F. (2009). Vitamin D status: measurement, interpretation, and clinical application. *Ann Epidemiol*, 19(2), 73-78. <https://doi.org/10.1016/j.annepidem.2007.12.001>
28. Holick, M. F. (2020). A call for action: standard of care guidelines to assess vitamin D status are needed for patients with hip fracture. *Am J Clin Nutr*, 112(3), 507-509. <https://doi.org/10.1093/ajcn/nqaa202>
29. Holick, M. F., Binkley, N. C., Bischoff-Ferrari, H. A., Gordon, C. M., Hanley, D. A., Heaney, R. P., Murad, M. H., & Weaver, C. M. (2011). Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*, 96(7), 1911-1930. <https://doi.org/10.1210/jc.2011-0385>
30. Javed, M., Althwanay, A., Ahsan, F., Oliveri, F., Goud, H. K., Mehkari, Z., Mohammed, L., & Rutkofsky, I. H. (2020). Role of Vitamin D in Colorectal Cancer: A Holistic Approach and Review of the Clinical Utility. *Cureus*, 12(9), e10734-e10734. <https://doi.org/10.7759/cureus.10734>
31. Krasowski, M. D. (2011). Pathology Consultation on Vitamin D Testing. *American Journal of Clinical Pathology*, 136(4), 507-514.
32. Kusunoki, Y., Matsui, I., Hamano, T., Shimomura, A., Mori, D., Yonemoto, S., Takabatake, Y., Tsubakihara, Y., St-Arnaud, R., Isaka, Y., & Rakugi, H. (2015). Excess 25-hydroxyvitamin D3 exacerbates tubulointerstitial injury in mice by modulating macrophage phenotype. *Kidney Int*, 88(5), 1013-1029. <https://doi.org/10.1038/ki.2015.210>
33. Looker, A. C., Johnson, C. L., Lacher, D. A., Pfeiffer, C. M., Schleicher, R. L., & Sempos, C. T. (2011). Vitamin D status: United States, 2001-2006. *NCHS Data Brief*(59), 1-8.
34. Madhusmita, M. (2024, October 30, 2024). *Vitamin D insufficiency and deficiency in children and adolescents*. Wolters Kluwer. <https://www.uptodate.com/contents/vitamin-d-insufficiency-and-deficiency-in-children-and-adolescents>
35. McNamara, M., & Rosenberger, K. D. (2019). The Significance of Vitamin D Status in Breast Cancer: A State of the Science Review. *J Midwifery Womens Health*, 64(3), 276-288. <https://doi.org/10.1111/jmwh.12968>

36. Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., Kushner, R. F., Richard, L., Pessah-Pollack, R., Seger, J., Urman, R. D., Adams, S., Cleek, J. B., Correa, R., Figaro, M. K., Flanders, K., Grams, J., Hurley, D. L., Kothari, S., . . . Still, C. D. (2019). Clinical Practice Guidelines For The Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures – 2019 Update: Cosponsored By American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society For Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists *. *Endocrine Practice*, 25, 1-75. <https://doi.org/10.4158/GL-2019-0406>
37. Moyer, V. A. (2013). Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*, 158(9), 691-696. <https://doi.org/10.7326/0003-4819-158-9-201305070-00603>
38. NHS. (2016). *Guidelines for the Treatment of Vitamin D Deficiency and Insufficiency*. <https://www.shropshiretelfordandwrekinccg.nhs.uk/wp-content/uploads/vitamin-d-guidance.pdf>
39. Nielsen, O. H., Hansen, T. I., Gubatan, J. M., Jensen, K. B., & Rejnmark, L. (2019). Managing vitamin D deficiency in inflammatory bowel disease. *Frontline Gastroenterol*, 10(4), 394-400. <https://doi.org/10.1136/flgastro-2018-101055>
40. Pazirandeh, S., & Burns, D. (2023, September 8, 2023). *Overview of vitamin D*. UptoDate. <https://www.uptodate.com/contents/overview-of-vitamin-d>
41. Ribeiro, H. G., Dantas-Komatsu, R. C. S., Medeiros, J. F. P., Carvalho, M. C. d. C., Soares, V. d. L., Reis, B. Z., Luchessi, A. D., & Silbiger, V. N. (2021). Previous vitamin D status and total cholesterol are associated with SARS-CoV-2 infection. *Clinica chimica acta; international journal of clinical chemistry*, 522, 8-13. <https://doi.org/10.1016/j.cca.2021.08.003>
42. Ross, A. C., Manson, J. E., Abrams, S. A., Aloia, J. F., Brannon, P. M., Clinton, S. K., Durazo-Arvizu, R. A., Gallagher, J. C., Gallo, R. L., Jones, G., Kovacs, C. S., Mayne, S. T., Rosen, C. J., & Shapses, S. A. (2011). The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab*, 96(1), 53-58. <https://doi.org/10.1210/jc.2010-2704>
43. Royal Osteoporosis Society. (2020). Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management. <https://theros.org.uk/media/ef2ideu2/ros-vitamin-d-and-bone-health-in-adults-february-2020.pdf>
44. Sahota, O. (2014). Understanding vitamin D deficiency. In *Age Ageing* (Vol. 43, pp. 589-591). <https://doi.org/10.1093/ageing/afu104>
45. Sanders, K. M., Stuart, A. L., Williamson, E. J., Simpson, J. A., Kotowicz, M. A., Young, D., & Nicholson, G. C. (2010). Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. *Jama*, 303(18), 1815-1822. <https://doi.org/10.1001/jama.2010.594>
46. Scott, M. G., Gronowski, A. M., Reid, I. R., Holick, M. F., Thadhani, R., & Phinney, K. (2015). Vitamin D: the more we know, the less we know. *Clin Chem*, 61(3), 462-465. <https://doi.org/10.1373/clinchem.2014.222521>

47. Scragg, R., Stewart, A. W., Waayer, D., Lawes, C. M. M., Toop, L., Sluyter, J., Murphy, J., Khaw, K. T., & Camargo, C. A., Jr. (2017). Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease in the Vitamin D Assessment Study : A Randomized Clinical Trial. *JAMA Cardiol*, 2(6), 608-616. <https://doi.org/10.1001/jamacardio.2017.0175>
48. Sempos, C. T., & Binkley, N. (2020). 25-Hydroxyvitamin D assay standardisation and vitamin D guidelines paralysis. *Public Health Nutr*, 23(7), 1153-1164. <https://doi.org/10.1017/s1368980019005251>
49. Sempos, C. T., Heijboer, A. C., Bikle, D. D., Bollerslev, J., Bouillon, R., Brannon, P. M., DeLuca, H. F., Jones, G., Munns, C. F., Bilezikian, J. P., Giustina, A., & Binkley, N. (2018). Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D. *Br J Clin Pharmacol*, 84(10), 2194-2207. <https://doi.org/10.1111/bcp.13652>
50. Szerszeń, M. D., Kucharczyk, A., Bojarska-Senderowicz, K., Pohorecka, M., Śliwczyński, A., Engel, J., Korcz, T., Kosior, D., Walecka, I., Zgliczyński, W. S., Wierzbą, W., & Sybilski, A. J. (2022). Effect of Vitamin D Concentration on Course of COVID-19. *Med Sci Monit*, 28, e937741. <https://doi.org/10.12659/msm.937741>
51. Trivedi, D. P., Doll, R., & Khaw, K. T. (2003). Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. *Bmj*, 326(7387), 469. <https://doi.org/10.1136/bmj.326.7387.469>
52. Ul Afshan, F., Nissar, B., Chowdri, N. A., & Ganai, B. A. (2021). Relevance of vitamin D(3) in COVID-19 infection. *Gene reports*, 24, 101270-101270. <https://doi.org/10.1016/j.genrep.2021.101270>
53. USPSTF. (2021). Screening for vitamin D deficiency in adults: U.S. Preventive Services Task Force recommendation statement. *Jama*, 325(14), 1436-1442. <https://doi.org/10.1001/jama.2021.3069>
54. Vernia, F., Valvano, M., Longo, S., Cesaro, N., Viscido, A., & Latella, G. (2022). Vitamin D in Inflammatory Bowel Diseases. Mechanisms of Action and Therapeutic Implications. *Nutrients*, 14(2). <https://doi.org/10.3390/nu14020269>
55. Wallace, A. M., Gibson, S., de la Hunty, A., Lamberg-Allardt, C., & Ashwell, M. (2010). Measurement of 25-hydroxyvitamin D in the clinical laboratory: current procedures, performance characteristics and limitations. *Steroids*, 75(7), 477-488. <https://doi.org/10.1016/j.steroids.2010.02.012>
56. Wassenaar, E., O'Melia, A. M., & Mehler, P. S. (2018). Gynecologic Care for Adolescents and Young Women With Eating Disorders. *Obstet Gynecol*, 132(4), 1065-1066. <https://doi.org/10.1097/aog.0000000000002903>
57. Weinstein, S. J., Purdue, M. P., Smith-Warner, S. A., Mondul, A. M., Black, A., Ahn, J., Huang, W. Y., Horst, R. L., Kopp, W., Rager, H., Ziegler, R. G., & Albanes, D. (2015). Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Int J Cancer*, 136(6), E654-664. <https://doi.org/10.1002/ijc.29157>
58. Yuniati, T., Judistiani, R. T. D., Natalia, Y. A., Irianti, S., Madjid, T. H., Ghazali, M., Sribudiani, Y., Indrati, A. R., Abdulah, R., & Setiabudiawan, B. (2019). First trimester maternal vitamin D, ferritin, hemoglobin level and their associations with neonatal birthweight: Result from cohort study on vitamin D status and its impact during pregnancy and childhood in Indonesia. *J Neonatal Perinatal Med*. <https://doi.org/10.3233/npm-180043>

59. Zhao, S., Gardner, K., Taylor, W., Marks, E., & Goodson, N. (2015). Vitamin D assessment in primary care: changing patterns of testing. *London J Prim Care (Abingdon)*, 7(2), 15-22. <https://doi.org/10.1080/17571472.2015.11493430>
60. Zittermann, A., Pilz, S., & Berthold, H. K. (2019). Serum 25-hydroxyvitamin D response to vitamin D supplementation in infants: a systematic review and meta-analysis of clinical intervention trials. *Eur J Nutr.* <https://doi.org/10.1007/s00394-019-01912-x>

Policy Update History

Approval Date	Effective Date; Summary of Changes
09/05/2025	01/01/2026: New policy.